IDEAS home Printed from https://ideas.repec.org/a/spr/drugsa/v39y2016i5d10.1007_s40264-015-0389-2.html
   My bibliography  Save this article

Maximizing the Post-Approval Safety of Flibanserin: A Role for Regulators, Clinicians, and Patients

Author

Listed:
  • Sheriza N. Baksh

    (Johns Hopkins University
    Johns Hopkins Bloomberg School of Public Health)

  • Walid F. Gellad

    (University of Pittsburgh
    VA Pittsburgh Healthcare System)

  • G. Caleb Alexander

    (Johns Hopkins University
    Johns Hopkins Bloomberg School of Public Health
    Johns Hopkins Medicine)

Abstract

In August 2015, the US Food and Drug Administration (FDA) made the controversial decision to approve flibanserin (Addyi®) for women experiencing hypoactive sexual desire disorder. A number of factors contributed to disagreements regarding the FDA’s decision, including the product’s two prior failed FDA reviews, the unmet need of women with this disorder, extensive advocacy and politicization surrounding the product’s relevance to women and sexual health, the potential for widespread off-label use, and the product’s tenuous risk/benefit profile. Despite that, attention now shifts to maximizing the safe use of the product, including the optimal means to avoid numerous drug–drug interactions as well as the concomitant use of alcohol, both of which potentiate the risks of dizziness, hypotension, and syncope. Although the FDA has implemented a comprehensive Risk Evaluation and Mitigation Strategies program to maximize the product’s safe use, patients, clinicians, and regulators must exhibit heightened vigilance early in the product’s post-market life.

Suggested Citation

  • Sheriza N. Baksh & Walid F. Gellad & G. Caleb Alexander, 2016. "Maximizing the Post-Approval Safety of Flibanserin: A Role for Regulators, Clinicians, and Patients," Drug Safety, Springer, vol. 39(5), pages 375-380, May.
    • Handle: RePEc:spr:drugsa:v:39:y:2016:i:5:d:10.1007_s40264-015-0389-2
    DOI: 10.1007/s40264-015-0389-2
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40264-015-0389-2
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40264-015-0389-2?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:39:y:2016:i:5:d:10.1007_s40264-015-0389-2. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.